Oncotelic Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.78 per share for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2019-05-15
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2019-03-31 was $4.78, a 490.12% increase year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.81, a 31.93% decline year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $1.19, a 64.16% decline year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-03-31 was $3.32.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $0.65, a 43.97% decline from fiscal 2017.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2017 was $1.16, a 33.33% decline from fiscal 2016.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $1.74, a 9.84% decline from fiscal 2015.
- Oncotelic Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2015 was $1.93, a 94.22% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2019-03-31 | $4.78 10-Q · filed 2019-05-15 | |||
| 2018-12-31 | $0.65 10-K · filed 2019-04-10 | |||
| 2018-09-30 | $0.61 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $0.69 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | $0.81 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $1.16 10-K · filed 2019-04-10 | |||
| 2017-09-30 | $1.27 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | $1.66 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | $1.19 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $1.74 10-K · filed 2018-04-17 | |||
| 2016-09-30 | $2.14 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $3.27 10-Q · filed 2016-08-02 | |||
| 2016-03-31 | $3.32 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | $1.93 10-K · filed 2017-03-30 | |||
| 2015-09-30 | $2.03 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $1.93 10-Q · filed 2015-08-06 | |||
| 2014-12-31 | $33.40 10-K · filed 2016-03-25 |